Biotech entity
Weiss Ratings is most often covered alongside Wall Street Zen, which appears in 13 of these 19 stories. Negative sentiment reaches 0% here, compared with 18% across the 284-story beat baseline for the same window. pharma accounts for 14 of the 19 tracked stories, while 3 other categories carry the remainder.
Last mentioned: 17h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Weiss Ratings is most often covered alongside Wall Street Zen, which appears in 13 of these 19 stories. Negative sentiment reaches 0% here, compared with 18% across the 284-story beat baseline for the same window. pharma accounts for 14 of the 19 tracked stories, while 3 other categories carry the remainder. Each story carries 2.1 original sources on average, compared with 3.5 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 6 for that window. Across a 67-day span, the pace is roughly 2 stories per week. The busiest single day carried 3. This profile follows 19 Biotech stories mentioning Weiss Ratings across the period from July 5, 2026 to September 9, 2026.
Computed from the 19 stories linked to this entity, with beat comparisons drawn from all 284 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Weiss Ratings. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen rating actions
Wall Street Zen upgraded Tenaya from strong sell to sell and argenx from hold to buy.
Deutsche Bank downgrades argenx
Deutsche Bank cut argenx from buy to hold.
Wall Street Zen upgrades both stocks to Hold
Wall Street Zen upgraded CTNM and ENVB from Sell to Hold in Sunday research notes.
Truist raises argenx target
Truist Financial lifted its argenx target from $1,030.00 to $1,095.00 with a buy rating.
Silexion reports quarterly results
Silexion reported a $5.17 loss per share, beating consensus estimates by $16.03; shares fell to $0.42.
Quarterly earnings release
Lantern Pharma reported quarterly EPS of ($0.57), missing consensus by $0.19; shares rose $0.02 to $2.65.
Q2 earnings released; EPS beats consensus
Company reported ($1.40) EPS versus ($1.55) consensus; shares rose $0.05 to $0.57 on 2.3x average volume
Tenaya Q2 miss
Tenaya reported EPS of -$0.20 versus -$0.07 expected and revenue of $1.11 million versus $10 million consensus.
RBC raises CTNM target to $23
Royal Bank of Canada raised its Contineum target from $22.00 to $23.00 with an Outperform rating.
Contineum reports Q2 results
Contineum reported Q2 EPS of -$0.40, beating consensus by $0.05.
Maxim Group downgrades to Hold
Maxim Group lowered Silexion Therapeutics from a Strong-Buy rating to a Hold rating.
Weiss Ratings upgrade
Weiss Ratings upgraded Lantern Pharma from 'sell (e+)' to 'sell (d-)'.
Baird raises argenx target
Robert W. Baird raised argenx target from $867.00 to $932.00 with a neutral rating.
argenx Q2 beat
argenx reported EPS of $7.32 versus $5.86 expected and revenue of $1.54 billion.
Weiss Ratings reiterates Sell
Restated a 'sell (e+)' rating on MBRX shares in a research note
Shares drop 1.8%
APYX traded as low as $4.34 and last at $4.38 on volume of 43,859 shares, 60% below average.
BofA lifts argenx target
Bank of America raised its price objective on argenx from $1,016.00 to $1,088.00 with a buy rating.
Schikan sells 30,712 shares
Schikan sold an additional 30,712 shares at $35.49, totaling $1,089,969.
Weiss Ratings reiterates sell
Weiss Ratings reissued a sell (d-) rating on Apyx Medical shares.
HC Wainwright reiterates buy rating
HC Wainwright reaffirmed its buy rating on Pharvaris shares.
Wall Street Zen upgraded Tenaya from strong sell to sell, but the micro-cap gene therapy company still trades near a 52-week low after a sharp Q2 EPS and revenue miss. Biotech readers get a closer look at how clinical-stage execution failures are reflected in rating actions, while argenx's profitable rare disease business shows what commercial success looks like.
Source: tickerreport.com · dailypolitical.com
A rare double upgrade by Wall Street Zen moved Contineum Therapeutics and Enveric Biosciences from Sell to Hold, offering a momentary reprieve for two money-losing clinical-stage biotechs. CTNM trades near its 52-week high at $17.19 with a $20.25 consensus target, while ENVB's psychedelic pipeline carries a $6.41M market cap against a former $17.64 high.
Source: themarketsdaily.com · tickerreport.com
I-Mab, a clinical-stage oncology and immunology biotech, reported a $(0.16) quarterly EPS on Aug 20. With shares at $1.91, H.C. Wainwright's reiterated $9 target implies massive upside, though Weiss remains bearish. Institutional ownership sits at 38.38%.
Source: Bbns · Ticker Report
Clinical-stage Moleculin Biotech is now valued at just $4.06 million after a 97% collapse from its 52-week high, raising existential questions about its ability to fund development of therapies for resistant tumors and viral infections. The EPS 'beat' of ($1.40) versus ($1.55) is a paper figure — no revenue, cash balance, or clinical milestone accompanied the report.
Source: dailypolitical.com · themarketsdaily.com
Lantern Pharma's $0.57 quarterly loss missed consensus by $0.19, underscoring clinical-stage risk. The micro-cap oncology company has no product revenue, and analysts maintain a Sell rating. Biotech investors need clarity on cash runway and upcoming trial catalysts.
Source: dailypolitical.com · themarketsdaily.com
Silexion reported a narrower-than-expected loss of $5.17 per share, but analysts downgraded the stock to Hold. Its RNAi LODER candidates remain preclinical or Phase I, and a $0.42 share price may constrain funding for further oncology development.
Source: tickerreport.com · dailypolitical.com
For biotech and pharma investors, Apyx Medical's Q1 loss of $0.05 per share beat consensus by $0.06, but the stock fell 1.8% to $4.38 on low volume. Mixed analyst ratings and a $6.50 consensus target raise questions about whether the small-cap device maker can convert clinical and operational beats into stock appreciation. Institutional repositioning signals ongoing evaluation of the company's commercial ramp.
Source: dailypolitical.com · tickerreport.com
SCYNEXIS shorts collapsed 87.6% to 320,181 shares, signaling bear exhaustion, while Ensysce Biosciences short interest exploded 619.9% to 364,278. Focus Universal also saw a 282.8% build, reflecting a stark divergence in microcap biotech sentiment.
Source: tickerreport.com · dailypolitical.com
A corporate insider at microcap HCW Biologics disclosed a $19,958.88 purchase of 7,736 shares at $2.58, but conflicting syndicated reports name different insiders. For biotech investors, the transaction highlights a high-risk stock trading 93% below its 52-week high despite a May EPS beat and a $30 Maxim target.
Source: themarketsdaily.com · dailypolitical.com
Shares of Entera Bio slipped 0.6% to $1.54 on 78% below-average volume, but analysts remain deeply split: HC Wainwright reiterates buy while Weiss Ratings maintains a sell. The $9.00 consensus target implies roughly 484% upside for the $75.91M microcap biotech.
Source: dailypolitical.com · tickerreport.com
Palvella Therapeutics stock sank 12.4% Monday with no news, highlighting biotech liquidity risk. Analyst consensus target of $199.53 implies 45% upside, but earnings miss and two sell ratings complicate the picture for biotech investors.
Source: dailypolitical.com · tickerreport.com
Analyst action pushes Talphera into the spotlight as a deeply undervalued biotech, with a $3.00 average target offering over 100% upside. Recent earnings beat and institutional buying add to the narrative. Two buy initiations from specialized firms highlight confidence in the pain management pipeline.
Source: themarketsdaily.com · dailypolitical.com
Short interest in CDT Equity, the ticker for clinical-stage biotech Conduit Pharmaceuticals, jumped 70.8% after the stock plunged from a $610 high to just $0.71. With a market cap of $3.45 million and no approved products, the spike in bearish bets underscores the deep skepticism around its early-stage pipeline for autoimmune diseases and infertility.
Source: themarketsdaily.com · tickerreport.com
Wall Street Zen upgraded biotech Agenus to buy despite a massive Q1 earnings miss, as the stock surged 189% from its 52-week low. Mixed analyst views and a $30 HC Wainwright target highlight the speculative upside in immuno-oncology.
Source: tickerreport.com · dailypolitical.com
Teva's fiscal 2026 EPS guidance, well below the Street's $2.17, raises red flags for biotech and pharma investors. However, a $42 average price target and stable revenue suggest a value play if the biosimilar pipeline delivers.
Source: tickerreport.com · themarketsdaily.com
Novavax was slapped with a sell rating by Wall Street Zen, even after beating Q1 revenue estimates by 49%. The downgrade highlights biotech skepticism toward small-cap vaccine players in a shifting market.
Source: dailypolitical.com · tickerreport.com
Director Johannes Schikan sold $1.33 million in Pharvaris stock just as the company approaches critical Phase 3 readouts for its oral HAE therapy. With analysts split and institutions buying, the insider move adds a wrinkle to the risk-reward calculus ahead of binary clinical data.
Source: The Lincolnian Online · Bbns
Biotech and life sciences investors face a paradox: ResMed’s stalwart medical device business is underpinned by low debt and high margins, yet analyst targets range from $225 to $321 as GLP-1 therapies threaten its patient base.
Source: Ticker Report · Watch List News
A $110,694 insider purchase by Financial Lp Hrt in Shuttle Pharmaceuticals boosts the owner’s stake to 78,597 shares just as the micro-cap trades near $2.90 lows. For biotech investors, this accumulation could reflect confidential knowledge about the radiation sensitizer pipeline's progress.
Source: Markets Daily · Daily Political
Weiss Ratings is linked from 19 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
